Donald J Buchsbaum

List of Publications by Year
in descending order

191 papers	7,808 citations	50170 46 h-index	71532 76 g-index
201 all docs	201 docs citations	201 times ranked	9762 citing authors

#	Article	IF	Citations
1	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone. Advances in Cancer Research, 2022, 153, 131-168.	1.9	4
2	Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. Journal of Biological Chemistry, 2021, 296, 100034.	1.6	35
3	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm, 2020, 1, 121-128.	3.1	16
4	STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer. Cancer Research, 2020, 80, 4355-4370.	0.4	17
5	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. Translational Oncology, 2020, 13, 100776.	1.7	19
6	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/Î²-catenin transcription, cancer cell growth, and tumor immunity. Drug Discovery Today, 2020, 25, 1521-1527.	3.2	39
7	Inhibition of the Wnt/Î²-catenin pathway enhances antitumor immunity in ovarian cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091379.	1.4	21
8	B7-H3-targeted Radioimmunotherapy of Human Cancer. Current Medicinal Chemistry, 2020, 27, 4016-4038.	1.2	5
9	Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1. Cancer Immunology, Immunotherapy, 2019, 68, 2081-2094.	2.0	28
10	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. Cancer Immunology, Immunotherapy, 2019, 68, 175-188.	2.0	25
11	Calmodulin antagonist enhances DR5â€mediated apoptotic signaling in TRAâ€8 resistant triple negative breast cancer cells. Journal of Cellular Biochemistry, 2018, 119, 6216-6230.	1.2	14
12	CD38 pretargeted RIT of B-cell tumors. Blood, 2018, 131, 589-590.	0.6	2
13	212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nuclear Medicine and Biology, 2018, 58, 67-73.	0.3	40
14	ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. Journal of Biological Chemistry, 2018, 293, 984-994.	1.6	68
15	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer, 2018, 124, 4657-4666.	2.0	22
16	Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling. Advances in Experimental Medicine and Biology, 2018, 1077, 87-113.	0.8	3
17	212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. International Journal of Molecular Sciences, 2018, 19, 925.	1.8	31
18	Preferential Inhibition of Wnt/Î²-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 1524.	1.8	35

#	Article	IF	Citations
19	Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells. Journal of Cellular Biochemistry, 2017, 118, 2285-2294.	1.2	7
20	B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nuclear Medicine and Biology, 2017, 47, 23-30.	0.3	52
21	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecologic Oncology Reports, 2017, 20, 81-86.	0.3	44
22	Modulation of antitumor immunity with histone deacetylase inhibitors. Immunotherapy, 2017, 9, 1359-1372.	1.0	37
23	Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. Clinical and Translational Medicine, 2017, 6, 11.	1.7	10
24	Journey of TRAIL from bench to bedside and its potential role in immuno-oncology. Oncology Reviews, 2017, 11, 332.	0.8	37
25	Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget, 2017, 8, 8226-8238.	0.8	69
26	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget, 2017, 8, 44159-44170.	0.8	41
27	Role of nanotechnology and gene delivery systems in TRAIL based therapies. Ecancermedicalscience, 2016, 10, 660.	0.6	16
28	Niclosamide and its analogs are potent inhibitors of Wnt/Î²-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget, 2016, 7, 86803-86815.	0.8	64
29	Surveying the serologic proteome in a tissueâ€specific kras(G12D) knockin mouse model of pancreatic cancer. Proteomics, 2016, 16, 516-531.	1.3	36
30	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. Cancer Research, 2016, 76, 3978-3988.	0.4	134
31	Ovarian cancer and the immune system â€" The role of targeted therapies. Gynecologic Oncology, 2016, 142, 349-356.	0.6	54
32	Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells. Journal of Biological Chemistry, 2016, 291, 12862-12870.	1.6	15
33	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with longâ€term survival and reveals a role for ANGPTL4. Molecular Oncology, 2016, 10, 1169-1182.	2.1	70
34	Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunology Research, 2016, 4, 390-399.	1.6	112
35	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2016, 15, 680-688.	1.9	49
36	Targeting the Wnt/Î²-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Laboratory Investigation, 2016, 96, 249-259.	1.7	58

#	Article	IF	Citations
37	A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. Molecular Imaging and Biology, 2016, 18, 325-333.	1.3	4
38	Loss of tumor suppressor Merlin results in aberrant activation of Wnt/Î²-catenin signaling in cancer. Oncotarget, 2016, 7, 17991-18005.	0.8	26
39	S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Scientific Reports, 2015, 5, 8453.	1.6	41
40	Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model. Journal of Visualized Experiments, 2015, , .	0.2	7
41	Niclosamide Analogs for Treatment of Ovarian Cancer. International Journal of Gynecological Cancer, 2015, 25, 1377-1385.	1.2	21
42	Ovarian and cervical cancer patient derived xenografts: The past, present, and future. Gynecologic Oncology, 2015, 138, 486-491.	0.6	37
43	Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. Journal of the Egyptian National Cancer Institute, 2015, 27, 205-215.	0.6	9
44	Pazopanib Combined with Radiation: In Vivo Model of Interaction. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 247-250.	0.7	7
45	Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biology and Therapy, 2014, 15, 1053-1060.	1.5	14
46	Antagonistic Effects of Anti-EMMPRIN Antibody When Combined with Chemotherapy Against Hypovascular Pancreatic Cancers. Molecular Imaging and Biology, 2014, 16, 85-94.	1.3	9
47	Will Detection of MicroRNA Biomarkers in Blood Improve the Diagnosis and Survival of Patients With Pancreatic Cancer?. JAMA - Journal of the American Medical Association, 2014, 311, 363.	3.8	10
48	Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic Oncology, 2014, 132, 203-210.	0.6	40
49	Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Research and Treatment, 2014, 146, 287-297.	1.1	141
50	Effect of Niclosamide on Basal-like Breast Cancers. Molecular Cancer Therapeutics, 2014, 13, 800-811.	1.9	78
51	Inhibition of Wnt/Î²-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecologic Oncology, 2014, 134, 112-120.	0.6	142
52	Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Letters, 2014, 349, 8-14.	3.2	303
53	Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?. World Journal of Stem Cells, 2014, 6, 441.	1.3	52
54	The Wnt/Î²-catenin pathway in ovarian cancer: A review. Gynecologic Oncology, 2013, 131, 772-779.	0.6	394

#	Article	IF	Citations
55	Lung Resistance-Related Protein (LRP) Expression in Malignant Ascitic Cells as a Prognostic Marker for Advanced Ovarian Serous Carcinoma. Annals of Surgical Oncology, 2013, 20, 3059-3065.	0.7	11
56	ST6Gal-I Protein Expression Is Upregulated in Human Epithelial Tumors and Correlates with Stem Cell Markers in Normal Tissues and Colon Cancer Cell Lines. Cancer Research, 2013, 73, 2368-2378.	0.4	139
57	Catalase Abrogates Î²-Lapachoneâ€“Induced PARP1 Hyperactivationâ€“Directed Programmed Necrosis in NQO1-Positive Breast Cancers. Molecular Cancer Therapeutics, 2013, 12, 2110-2120.	1.9	85
58	The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/Î²-Catenin Signaling in Cancer Cells. PLoS ONE, 2013, 8, e58102.	1.1	12
59	Cancer Treatment with Gene Therapy and Radiation Therapy. Advances in Cancer Research, 2012, 115, 221-263.	1.9	64
60	The Use of Retinoids in Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 191-198.	1.2	5
61	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecologic Oncology, 2012, 127, 420-425.	0.6	64
62	Progress in Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 1-1.	0.7	3
63	A Deimmunized Bispecific Ligand-Directed Toxin That Shows an Impressive Antiâ€“Pancreatic Cancer Effect in a Systemic Nude Mouse Orthotopic Model. Pancreas, 2012, 41, 789-796.	0.5	15
64	Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast Cancer Research and Treatment, 2012, 133, 417-426.	1.1	33
65	Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Research and Treatment, 2012, 133, 437-445.	1.1	23
66	The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecologic Oncology, 2012, 125, 226-230.	0.6	27
67	Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiotherapy and Oncology, 2011, 101, 183-189.	0.3	4
68	Cellular Model of Warburg Effect Identifies Tumor Promoting Function of UCP2 in Breast Cancer and Its Suppression by Genipin. PLoS ONE, 2011, 6, e24792.	1.1	123
69	Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Molecular Imaging, 2011, 10, 7290.2010.00040.	0.7	23
70	Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecologic Oncology, 2011, 121, 193-199.	0.6	11
71	DCE-MRI Detects Early Vascular Response in Breast Tumor Xenografts Following Anti-DR5 Therapy. Molecular Imaging and Biology, 2011, 13, 94-103.	1.3	28
72	Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer. Expert Review of Anticancer Therapy, 2011, 11, 1193-1196.	1.1	7

#	Article	IF	Citations
73	Mechanisms of Drug Sensitization to TRA-8, an Agonistic Death Receptor 5 Antibody, Involve Modulation of the Intrinsic Apoptotic Pathway in Human Breast Cancer Cells. Molecular Cancer Research, 2011, 9, 403-417.	1.5	29
74	Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biology and Therapy, 2011, 11, 431-449.	1.5	40
75	Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L79-L90.	1.3	18
76	Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular Imaging, 2011, 10, 153-67.	0.7	18
77	A New Drug Delivery Method of Bispecific Ligand-Directed Toxins, Which Reduces Toxicity and Promotes Efficacy in a Model of Orthotopic Pancreatic Cancer. Pancreas, 2010, 39, 913-922.	0.5	11
78	KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clinical and Experimental Metastasis, 2010, 27, 591-600.	1.7	60
79	Overcoming TRAIL resistance in ovarian carcinoma. Gynecologic Oncology, 2010, 119, 157-163.	0.6	23
80	Polyethylene Glycosylated Curcumin Conjugate Inhibits Pancreatic Cancer Cell Growth through Inactivation of Jab1. Molecular Pharmacology, 2009, 76, 81-90.	1.0	103
81	Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy, 2009, 1, 223-239.	1.0	35
82	Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer. Clinical Cancer Research, 2009, 15, 4058-4065.	3.2	55
83	Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression. Molecular Cancer Therapeutics, 2009, 8, 3130-3139.	1.9	27
84	In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts. Orl, 2009, 71, 1-5.	0.6	9
85	Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecologic Oncology, 2009, 113, 384-390.	0.6	33
86	Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer. Journal of Immunology, 2009, 182, 7548-7557.	0.4	68
87	Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model. International Journal of Gynecological Cancer, 2009, 19, 814-819.	1.2	16
88	Cancer gene therapy. , 2009, , 589-612.		2
89	In Reply to Dr. Speer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1274.	0.4	0
90	Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5. International Journal of Radiation Oncology Biology Physics, 2008, 71, 507-516.	0.4	29

#	Article	IF	Citations
91	Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecologic Oncology, 2008, 108, 591-597.	0.6	18
92	Molecular targeted therapies for pancreatic cancer. American Journal of Surgery, 2008, 196, 430-441.	0.9	45
93	Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine, 2008, 26, 4314-4319.	1.7	19
94	Early Therapy Evaluation of Combined Antiâ€"Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging. Cancer Research, 2008, 68, 8369-8376.	0.4	45
95	Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Molecular Cancer Therapeutics, 2008, 7, 2845-2854.	1.9	27
96	Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11. Clinical Cancer Research, 2008, 14, 2180-2189.	3.2	32
97	Combination Treatment with TRA-8 Antiâ€"Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer. Clinical Cancer Research, 2007, 13, 5535s-5543s.	3.2	37
98	TRAIL-receptor antibodies as a potential cancer treatment. Future Oncology, 2007, 3, 405-409.	1.1	28
99	Single-photon emission computed tomography imaging with a humanized, Apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. Cancer Biology and Therapy, 2007, 6, 1392-1398.	1.5	4
100	ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biology and Therapy, 2007, 6, 548-554.	1.5	87
101	TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Molecular Cancer Therapeutics, 2007, 6, 3198-3207.	1.9	42
102	High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99mâ€"labeled anti-DR5 antibody in breast tumor xenografts. Molecular Cancer Therapeutics, 2007, 6, 866-875.	1.9	23
103	Brief Overview of Preclinical and Clinical Studies in the Development of Intraperitoneal Radioimmunotherapy for Ovarian Cancer. Clinical Cancer Research, 2007, 13, 5643s-5645s.	3.2	31
104	EGFR Genomic Gain and Aberrant Pathway Signaling in Pancreatic Cancer Patients. Journal of Surgical Research, 2007, 143, 20-26.	0.8	32
105	Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecologic Oncology, 2007, 105, 291-298.	0.6	41
106	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecologic Oncology, 2007, 106, 614-621.	0.6	21
107	Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery, 2007, 141, 464-469.	1.0	60
108	Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response. Annals of Surgical Oncology, 2007, 14, 2150-2158.	0.7	46

#	Article	IF	Citations
109	Multiple Gene Expression Analyses in Paraffin-Embedded Tissues by TaqMan Low-Density Array. Journal of Molecular Diagnostics, 2006, 8, 76-83.	1.2	76
110	TRAIL receptor-targeted therapy. Future Oncology, 2006, 2, 493-508.	1.1	46
111	Pretargeted radioimmunotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, S57-S59.	0.4	25
112	Treatment With Gemcitabine and TRA-8 Anti-Death Receptor-5 mAb Reduces Pancreatic Adenocarcinoma Cell Viability In Vitro and Growth In Vivo. Journal of Gastrointestinal Surgery, 2006, 10, 1291-1300.	0.9	16
113	Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecologic Oncology, 2006, 101, 46-54.	0.6	47
114	Inducible Resistance of Tumor Cells to Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand Receptor 2â€"Mediated Apoptosis by Generation of a Blockade at the Death Domain Function. Cancer Research, 2006, 66, 8520-8528.	0.4	58
115	Gene delivery and gene therapy of prostate cancer. Expert Opinion on Drug Delivery, 2006, 3, 37-51.	2.4	7
116	Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein. Clinical Cancer Research, 2005, 11, 8180-8185.	3.2	25
117	Intraperitoneal Radioimmunotherapy with a Humanized Anti-TAG-72 (CC49) Antibody with a Deleted CH2 Region. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 502-513.	0.7	23
118	The Small Heat Shock Protein Î±B-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3. Journal of Biological Chemistry, 2005, 280, 11059-11066.	1.6	196
119	Antitumor Efficacy of Capecitabine and Celecoxib in Irradiated and Lead-Shielded, Contralateral Human BxPC-3 Pancreatic Cancer Xenografts: Clinical Implications of Abscopal Effects. Clinical Cancer Research, 2005, 11, 8773-8781.	3.2	63
120	Radiotargeted gene therapy. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 179S-86S.	2.8	8
121	Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Molecular Therapy, 2004, 10, 1059-1070.	3.7	25
122	Gene expression imaging with radiolabeled peptides. Annals of Nuclear Medicine, 2004, 18, 275-283.	1.2	11
123	Adenoviral vectorâ€"mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. International Journal of Radiation Oncology Biology Physics, 2004, 58, 950-958.	0.4	11
124	Anti-EGFRâ€"mediated radiosensitization as a result of augmented EGFR expression. International Journal of Radiation Oncology Biology Physics, 2004, 59, S2-S10.	0.4	36
125	Mechanisms of resistance to Erbitux (anti?epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. Journal of Gastrointestinal Surgery, 2004, 8, 960-970.	0.9	39
126	Site-Specifically Traced Drug Release and Biodistribution of a Paclitaxelâ^'Antibody Conjugate toward Improvement of the Linker Structure1. Bioconjugate Chemistry, 2004, 15, 1264-1274.	1.8	30

#	Article	IF	Citations
127	Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Seminars in Nuclear Medicine, 2004, 34, 32-46.	2.5	22
128	An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1037-1050.	0.4	36
129	Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene, 2003, 22, 2034-2044.	2.6	152
130	Synthesis and Biological Evaluation of Paclitaxelâ˜'C225 Conjugate as a Model for Targeted Drug Delivery1. Bioconjugate Chemistry, 2003, 14, 302-310.	1.8	78
131	Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. Journal of Surgical Research, 2003, 111, 274-283.	0.8	43
132	Three-Dimensional Dose Model for the Comparison of 177Lu-HuCC49Î"CH2 and 177Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 239-247.	0.7	3
133	Cancer gene therapy. , 2003, , 583-613.		1
134	Invited commentary: targeting of 125I-labeled B lymphocyte stimulator. Journal of Nuclear Medicine, 2003, 44, 434-6.	2.8	1
135	Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clinical Cancer Research, 2003, 9, 3731-41.	3.2	115
136	Adenovirus-Mediated Transfer of BAX Driven by the Vascular Endothelial Growth Factor Promoter Induces Apoptosis in Lung Cancer Cells. Molecular Therapy, 2002, 6, 190-198.	3.7	33
137	Gamma Camera Dual Imaging with a Somatostatin Receptor and Thymidine Kinase after Gene Transfer with a Bicistronic Adenovirus in Mice. Radiology, 2002, 223, 417-425.	3.6	72
138	Synthesis of the First Diethylenetriaminepentahydroxamic Acid (DTPH) Bifunctional Chelating Agentâ€,Â§. Bioconjugate Chemistry, 2002, 13, 327-332.	1.8	7
139	De Novo Synthesis of a New Diethylenetriaminepentaacetic Acid (DTPA) Bifunctional Chelating Agent. Bioconjugate Chemistry, 2002, 13, 317-326.	1.8	24
140	Quantitation of Cytosine Deaminase mRNA by Real-Time Reverse Transcription Polymerase Chain Reaction: A Sensitive Method for Assessing 5-Fluorocytosine Toxicity in Vitro. Analytical Biochemistry, 2002, 301, 189-199.	1.1	5
141	Targeted radiotherapy with [90Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer, 2002, 94, 1298-1305.	2.0	42
142	Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer, 2002, 94, 1332-1348.	2.0	115
143	Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1180-1193.	0.4	107
144	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Research, 2002, 62, 773-80.	0.4	91

#	Article	IF	Citations
145	Gene Therapy for the Treatment of Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 275-288.	0.7	14
146	Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. Nuclear Medicine and Biology, 2001, 28, 135-144.	0.3	28
147	A Noninvasive Reporter System to Image Adenoviral-Mediated Gene Transfer to Ovarian Cancer Xenografts. Gynecologic Oncology, 2001, 83, 432-438.	0.6	47
148	An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene Expression. Molecular Therapy, 2001, 4, 223-231.	3.7	119
149	Experimental radioimmunotherapy. Seminars in Radiation Oncology, 2000, 10, 156-167.	1.0	23
150	A Targetable, Injectable Adenoviral Vector for Selective Gene Delivery to Pulmonary Endothelium in Vivo. Molecular Therapy, 2000, 2, 562-578.	3.7	203
151	An Adenovirus Encoding Proapoptotic Bax Induces Apoptosis and Enhances the Radiation Effect in Human Ovarian Cancer. Molecular Therapy, 2000, 1, 545-554.	3.7	59
152	A ROBUST SUMMARIZEâ€“REGRESS PROCEDURE FOR TISSUE-SPECIFIC PHARMACOKINETICS. Journal of Biopharmaceutical Statistics, 2000, 10, 251-264.	0.4	0
153	Radionuclide Dosimetry and Radioimmunotherapy of Cancer. , 2000, , 21-55.		2
154	Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 451-463.	0.7	136
155	Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-Nâ€²,Nâ€³,Nâ€´-tris(acetic acid)cyclododecane (PA-DOTA). Bioorganic and Medicinal Chemistry, 1999, 7, 2313-2320.	1.4	41
156	Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Therapy, 1999, 6, 209-219.	2.2	29
157	Further Studies on the Protein Conjugation of Hydroxamic Acid Bifunctional Chelating Agents:â€‰ Group-Specific Conjugation at Two Different Loci. Bioconjugate Chemistry, 1999, 10, 18-23.	1.8	14
158	Paclitaxel Derivatives for Targeted Therapy of Cancer:Â Toward the Development of Smart Taxanesâ€. Journal of Medicinal Chemistry, 1999, 42, 4919-4924.	2.9	98
159	Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Current Opinion in Oncology, 1999, 11, 187.	1.1	15
160	Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells,. Journal of Gastrointestinal Surgery, 1998, 2, 283-291.	0.9	16
161	Radiosensitization mediated by a transfected Anti-erbB-2 single-chain antibody in vitro and in vivo. International Journal of Radiation Oncology Biology Physics, 1998, 42, 817-822.	0.4	23
162	Synthesis and Biodistribution of Peptide based 99mTc/186Re-MAGIPG-D612 Monoclonal Antibody in Nude Mice Bearing Colon Cancer Xenografts. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 55-62.	0.7	4

#	Article	IF	Citations
163	Conjugation of Unprotected Trisuccin,N-[Tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic Acid, to Monoclonal Antibody CC49 by an Improved Active Ester Protocol. Bioconjugate Chemistry, 1997, 8, 766-771.	1.8	7
164	Synthesis, Rhenium-188 Labeling and Biodistribution Studies of a Phenolic Ester Derivative of Trisuccin. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 375-384.	0.7	2
165	Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer, 1997, 80, 2354-2359.	2.0	39
166	Experimental tumor targeting with radiolabeled ligands. Cancer, 1997, 80, 2371-2377.	2.0	25
167	Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector. Cancer, 1997, 80, 2419-2424.	2.0	21
168	Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer, 1997, 80, 2567-2575.	2.0	8
169	A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. International Journal of Radiation Oncology Biology Physics, 1996, 35, 165-172.	0.4	13
170	Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies. International Journal of Peptide and Protein Research, 1996, 48, 79-86.	0.1	3
171	Dosimetry of Radiolabeled Antibodies. Medical Radiology, 1995, , 365-384.	0.0	5
172	A peptide-based bifunctional chelating agent for99mtc- and186re-labeling of monoclonal antibodies. Cancer, 1994, 73, 769-773.	2.0	24
173	Radioiodination of monoclonal antibodies d612 and 17-1a with 3-Iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice. Cancer, 1994, 73, 808-815.	2.0	15
174	Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformity. Cancer, 1994, 73, 912-918.	2.0	21
175	Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Cancer, 1994, 73, 999-1005.	2.0	20
176	Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. International Journal of Radiation Oncology Biology Physics, 1993, 25, 629-638.	0.4	30
177	New azomycin acyclonucleoside. Synthesis and biodistribution of radiohalogenated analogues in tumorâ€bearing mice. Journal of Heterocyclic Chemistry, 1993, 30, 1351-1355.	1.4	6
178	Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. Bioconjugate Chemistry, 1993, 4, 194-198.	1.8	14
179	Experimental radioimmunotherapy. Medical Physics, 1993, 20, 551-567.	1.6	48
180	Introduction: Radiolabeled antibody tumor dosimetry. Medical Physics, 1993, 20, 499-501.	1.6	6

#	Article	IF	Citations
181	Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodies. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1992, 43, 1387-1391.	0.5	5
182	Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography. International Journal of Radiation Oncology Biology Physics, 1992, 24, 329-334.	0.4	32
183	18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer, 1991, 67, 1544-1550.	2.0	200
184	A sensitivity study of micro-TLDs for in vivo dosimetry of radioimmunotherapy. Medical Physics, 1991, 18, 1195-1199.	1.6	8
185	Comparison of Antigen Expression on Normal Urothelial Cells in Tissue Section and Tissue Culture. Journal of Urology, 1990, 144, 1288-1292.	0.2	40
186	A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. International Journal of Radiation Oncology Biology Physics, 1990, 18, 1033-1041.	0.4	44
187	Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins. International Journal of Radiation Oncology Biology Physics, 1987, 13, 1701-1712.	0.4	10
188	Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium. European Journal of Nuclear Medicine and Molecular Imaging, 1985, 10-10, 398-402.	2.2	16
189	Localization of Radiolabeled Antibody in SVT2 Tumor Increases with Immunosuppression of the Host. Experimental Biology and Medicine, 1982, 171, 56-64.	1.1	1
190	Localization of an 125I-Labeled Rat Transplantation Antibody in Tumors Carrying the Corresponding Antigen. Experimental Biology and Medicine, 1972, 139, 1185-1188.	1.1	14
191	Effect of Rat Tumor Allografts on the Blood Level of Passively Transferred Alloantibodies. Experimental Biology and Medicine, 1972, 139, 1197-1201.	1.1	0